0.6600NOK-24.14%Mkt Cap: 73.62M NOKP/E: —Last update: 2026-06-01
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an ap…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap73.62M NOK
Enterprise Value31.13M NOK
Revenue (TTM)59.00K NOK
Gross Profit59.00K NOK
Net Income (TTM)-86.97M NOK
Revenue/Share0.0010 NOK
Last Price0.6600 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees11
CountryNO
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.38
EV/Revenue527.58
P/S1644.80
P/B1.79
EPS (TTM)-0.88
EPS (Forward)—
52W Range
0.60002% of range3.280
52W High3.280 NOK
52W Low0.6000 NOK
Profitability
Gross Margin100.00%
Oper. Margin-66142.46%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-283.21%
ROA-129.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.99M NOK
CapEx (TTM)5.32M NOK
FCF Margin-94387.52%
FCF Yield-75.64%
Net Debt-23.91M NOK
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.01
Current Ratio1.65
Quick Ratio0.85
Book Value/Sh0.4850 NOK
Cash/Share0.3850 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split250:1
Split DateJul 27, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.111.54M
Float16.23M
Insiders33.68%
Institutions12.54%
Technical
SMA 501.591 (-58.5%)
SMA 2001.838 (-64.1%)
Beta0.14
S&P 52W Chg27.70%
Avg Vol (30d)98.88K
Avg Vol (10d)151.51K
Technical Indicators
RSI (14)23.0
MACD-0.0874
MACD Signal-0.0748
MACD Hist.-0.0125
BB Upper1.619 NOK
BB Middle1.355 NOK
BB Lower1.090 NOK
BB Width39.08%
ATR (14)0.1629 NOK
Vol Ratio (20d)8.72x